News
- Author:
- Neil Osterweil
Publish date: November 15, 2023
Body weight reduction of at least 3% within 8 weeks of beginning treatment with either an SLT-2 or GLP-1 agent was associated independently with no...
News
- Author:
- Neil Osterweil
Publish date: November 9, 2023
“In the absence of effective treatments, health systems should plan for large increases in the number of liver cancer cases and the need for liver ...
News
- Author:
- Neil Osterweil
Publish date: November 6, 2023
Results of the randomized trial suggest that clinicians can safely prescribe empiric piperacillin-tazobactam for serious acute infections.
News
- Author:
- Neil Osterweil
Publish date: November 1, 2023
Race-specific equations may falsely inflate percent-predicted pulmonary function values in non-White patients, investigators caution.
News
- Author:
- Neil Osterweil
Publish date: October 25, 2023
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant metastati...
News
- Author:
- Neil Osterweil
Publish date: October 23, 2023
Patients cured of nontuberculosis mycobacterial infections with antibiotics had greater species diversity in sputum than those with refractory dise...
News
- Author:
- Neil Osterweil
Publish date: October 22, 2023
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk br...
News
- Author:
- Neil Osterweil
Publish date: October 22, 2023
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without atezolizumab...
News
- Author:
- Neil Osterweil
Publish date: October 20, 2023
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy alon...
News
- Author:
- Neil Osterweil
Publish date: October 18, 2023
SGM respondents were significantly more likely to have had asthma attacks requiring steroid use in the past years.
News
- Author:
- Neil Osterweil
Publish date: October 18, 2023
The presence of PH was associated with about a 50% higher risk for in-hospital mortality.
News
- Author:
- Neil Osterweil
Publish date: October 13, 2023
The first therapy to target the underlying pathology of Friedreich ataxia was approved in 2023. Other drug and genetic therapies are in the pipelin...
News
- Author:
- Neil Osterweil
Publish date: October 11, 2023
Patients with idiopathic pulmonary fibrosis who required dose reductions had similar all-cause mortality and death rates vs. patients on the full d...
News
- Author:
- Neil Osterweil
Publish date: October 10, 2023
What we eat and what’s in the gut may influence lung health for better or worse.
News
- Author:
- Neil Osterweil
Publish date: October 9, 2023
A randomized controlled trial conducted in low- to middle-income countries showed that 11.5 days could be safely shaved off a conventional fraction...
